IP Update

Premium

Title: RNA Interference Agents for Therapeutic Use

Patent Number: 7,951,784

Filed: Jan. 26, 2007

Lead Inventor: Tariq Rana, University of Massachusetts (RXi Pharmaceuticals)

“The invention features chemically modified small interfering RNAs that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA,” the patent's abstract states. “The featured siRNA are effective therapeutics, particularly for targeting SOD1.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.